SCHEMBL15417758

SCHEMBL15417758

CCc1cnc(C(N)=O)cc1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS3 P29474 1/20 0.56
▸ NOS1 P29475 1/20 0.56
▸ NOS2 P35228 1/20 0.56
▸ ADORA3 P0DMS8 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ MC4R P32245 1/20 0.41
▸ ADRA1A P35348 1/20 0.41
▸ MC3R P41968 1/20 0.41
▸ SIRT6 Q8N6T7 2/20 0.41
▸ LCK P06239 1/20 0.39
▸ GABRP O00591 1/20 0.39
▸ GABRD O14764 1/20 0.39
▸ GABRA1 P14867 1/20 0.39
▸ GABRB1 P18505 1/20 0.39
▸ GABRG2 P18507 1/20 0.39
▸ GABRB3 P28472 1/20 0.39
▸ GABRA5 P31644 1/20 0.39
▸ GABRA3 P34903 1/20 0.39
▸ GABRA2 P47869 1/20 0.39
▸ GABRB2 P47870 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3407724 0.83 IKBKB (0.40) NOS3NOS1NOS2ADORA3TSHR
SCHEMBL30625387 0.82 NOS3 (0.48) NOS3NOS1NOS2ADORA3TSHR
SCHEMBL1179407 0.81 NOS3 (0.51) NOS3NOS1NOS2GABRPGABRD
SCHEMBL24959359 0.80 SIRT6 (0.40) NOS3NOS1NOS2ADORA3TSHR
SCHEMBL17553883 0.79 NOS3 (0.49) NOS3NOS1NOS2TSHRPDCD1
SCHEMBL1425475 0.79 GABRA1 (0.51) NOS3NOS1NOS2GABRPGABRD
SCHEMBL24027065 0.78 NOS3 (0.52) NOS3NOS1NOS2GABRPGABRD
SCHEMBL24959354 0.77 SIRT6 (0.49) TSHRSIRT6PDCD1CD274
SCHEMBL23948608 0.77 UHRF1 (0.52) NOS3NOS1NOS2ADORA3TSHR
SCHEMBL11416280 0.76 KDM4E (0.41) NOS3NOS1NOS2ADORA3TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206175-B2 Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof GENENTECH, INC. (US) 2015-12-08 — — US disclosed
US-20140088076-A1 SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2014-03-27 — — US disclosed
US-8623889-B2 Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof GENENTECH, INC. (US) 2014-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140088076-A1 SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF XDH, CYP2B6, COX6B1 NOS3 50/4885NOS1 209/4885NOS2 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback